U.S. Patent 5,057,616 — Overview
U.S. Patent 5,057,616, granted to Merck Sharp & Dohme in 1991, protects a lipid-lowering drug, specifically a formulation involving lovastatin. The patent's main claims encompass the chemical composition, methods of manufacturing, and therapeutic application of lovastatin derivatives.
Scope of the Patent Claims
Core Claims
The patent primarily covers the following:
- Chemical Composition: The specific crystalline form of lovastatin, including its preparation and purity.
- Method of Synthesis: Specific processes to produce high-purity crystalline lovastatin.
- Therapeutic Use: The application of lovastatin for lowering serum cholesterol levels.
- Pharmaceutical Formulations: Dosage forms containing lovastatin, including tablets and capsules.
Claim Breakdown
The claims are divided as follows:
- Chemical Claims: Cover the crystalline form of lovastatin with specified characteristics, such as melting point and crystal morphology.
- Process Claims: Describe methods for synthesizing crystalline lovastatin, emphasizing reaction conditions like solvents and purification steps.
- Use Claims: Claim the use of crystalline lovastatin for hypercholesterolemia treatment.
- Formulation Claims: Cover specific pharmaceutical compositions comprising crystalline lovastatin.
Limitations
The claims explicitly specify crystalline lovastatin with certain physical parameters, restricting infringement to formulations matching those characteristics. Method claims are limited to the described synthesis conditions, preventing overlap with alternative synthetic routes.
Patent Landscape for Lovastatin and Related Statins
Patent Family and Related Patents
The original '616 patent forms the foundation for subsequent patent filings:
| Patent Number |
Filing Year |
Issued Year |
Scope |
Assignee |
| 5,057,616 |
1987 |
1991 |
Crystal form, synthesis, therapeutic use |
Merck Sharp & Dohme |
| 4,648,868 |
1985 |
1987 |
Lovastatin synthesis, natural source extraction |
Merck |
| 5,202,238 |
1993 |
1993 |
Second-generation formulations, derivatives |
Merck |
The '616 patent was complemented by later patents, including formulations with extended-release mechanisms and combination therapies.
Patent Expiry Timeline
Most primary claims related to lovastatin's crystalline form and synthesis have expired or will expire soon:
| Patent Number |
Expiry Date (Estimated) |
Comments |
| 5,057,616 |
June 8, 2008 |
Term based on filing date, excluding possible patent term adjustments |
| Related patents |
Varying, primarily between 2008-2013 |
Expired or nearing expiry |
Expired patents open the pathway for generic companies to produce lovastatin formulations wholesale.
Competitive Patent Strategies
Current patent activity emphasizes:
- New Formulations: Extended-release versions and combination therapies.
- ARV and Biosimilar Patents: For newer statins like atorvastatin and rosuvastatin.
- Method of Use: Patents covering specific health indications, including combination therapies or biomarkers.
Legal and Litigation Landscape
The '616 patent has faced litigation challenges primarily from generic manufacturers post-expiration. WHOOPs include:
- Invalidity assertions based on prior art.
- Challenges over patent term extensions.
Merck employed patent litigation until the patent's expiration, delaying generic competition. After expiry, numerous manufacturers entered the market with generic lovastatin.
Current Status and Implications
The expiration of the '616 patent has facilitated broad generic competition in the US. Several companies now market generic lovastatin at significantly reduced prices. Patent filings related to newer formulations or extensions secure market exclusivity for subsequent innovations, often targeting improved lipid control and patient adherence.
Key Takeaways
- The '616 patent covered crystalline lovastatin, synthesis methods, and therapeutic uses, with claims specific to particular physical and chemical characteristics.
- Most claims expired by 2008, opening the US market for generic lovastatin.
- The patent landscape shifted toward new formulations, delivery systems, and combination therapies to extend market exclusivity.
- Legal battles primarily suppressed generic entry until patent expirations allowed market renewal.
- Strategic patenting continues around advanced formulations and new indications for statins.
FAQs
1. What is the core innovation covered by U.S. Patent 5,057,616?
The patent claims a specific crystalline form of lovastatin, a process for its synthesis, and its use in lowering cholesterol.
2. When did the patent expire?
The patent expired on June 8, 2008, based on standard patent term calculations.
3. How does the patent landscape impact generic lovastatin availability?
Post-expiration, multiple generic manufacturers entered the market, leading to reduced prices and increased accessibility.
4. Are there still active patents preventing generic entry?
Yes. Patents on new formulations, extended-release forms, or combination therapies are active and protect newer products.
5. How have subsequent patents extended the commercial life of statins?
Through formulations with improved bioavailability, delivery mechanisms, or additional therapeutic claims.
References
- United States Patent and Trademark Office. Patent No. 5,057,616.
- patents.google.com. Patent landscape on lovastatin and statins.
- FDA Approved Drug Products. Lovastatin information.
- U.S. Patent Office. Patent expiry data.
- Market reports on generic statins.
[1] USPTO Patent No. 5,057,616
[2] Google Patents, lovastatin patents
[3] FDA, Lovastatin drug approval data
[4] Patent expiry timelines from public patent databases
[5] Industry market analysis reports
